[Resolution of liver metastases in response to S-1 monotherapy in advanced pancreatic cancer--a case report].
We report a case in a late phase II clinical study investigating the efficacy and safety of the oral fluoropyrimidine anticancer drug S-1. The drug proved effective in a patient with inoperable advanced pancreatic cancer in whom radiation therapy was not indicated. The antitumor effect after 4 courses was rated excellent, with a target site (liver) evaluation of CR and overall evaluation of PR. In particular, two liver metastases, measuring 18.7 x 15.4 mm and 16.2 x 14.6 mm, respectively, both resolved, and S-1 was found to exert a potent antitumor effect against metastases. Assessment of adverse events revealed no grade 3 or 4 adverse reactions, and other adverse events were all mild. Based on the above results, S-1 appeared to be effective against advanced pancreatic cancer and showed excellent tolerability.
Mizuno
Nobumasa
N
Dept. of Gastroenterology, Aichi Cancer Center Hospital.
Sawaki
Akira
A
Yamao
Kenji
K
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D017322:Clinical Trials, Phase II as Topic; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction; D005641:Tegafur / Q000008:administration & dosage*
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid